Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Page 1
Leaking in Intimate Partner Homicide: A Systematic Review.
Rumpf T, Horn S, Vogt C, Göbel K, Görgen T, Zibulski KM, Uttenweiler V, Bondü R. Rumpf T, et al. Among authors: gobel k. Trauma Violence Abuse. 2024 Mar 29:15248380241237213. doi: 10.1177/15248380241237213. Online ahead of print. Trauma Violence Abuse. 2024. PMID: 38551126 Review.
We identified 47 relevant publications via a systematic search of eight databases and additional methods. We included publications that did not explicitly use the term, but described behaviors that could be interpreted as leaking. ...
We identified 47 relevant publications via a systematic search of eight databases and additional methods. We included publications that did …
Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis.
Hundehege P, Fernandez-Orth J, Römer P, Ruck T, Müntefering T, Eichler S, Cerina M, Epping L, Albrecht S, Menke AF, Birkner K, Göbel K, Budde T, Zipp F, Wiendl H, Gorji A, Bittner S, Meuth SG. Hundehege P, et al. Among authors: gobel k. Neurosignals. 2018;26(1):77-93. doi: 10.1159/000495425. Epub 2018 Nov 27. Neurosignals. 2018. PMID: 30481775 Free article. Review.
RESULTS: Both prophylactic and therapeutic treatments ameliorated the clinical symptoms of EAE and reduced immune cell infiltration into the CNS. On neuronal level, pregabalin reduced long-term potentiation in hippocampal brain slices indicating an impact on mechanisms of …
RESULTS: Both prophylactic and therapeutic treatments ameliorated the clinical symptoms of EAE and reduced immune cell infiltration into the …
Long-term effects of dalfampridine in patients with multiple sclerosis.
Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, Meuth SG. Ruck T, et al. Among authors: gobel k. J Neurol Sci. 2014 Feb 15;337(1-2):18-24. doi: 10.1016/j.jns.2013.11.011. Epub 2013 Nov 16. J Neurol Sci. 2014. PMID: 24290498
BACKGROUND/OBJECTIVE: Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalf …
BACKGROUND/OBJECTIVE: Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of …
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: gobel k. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765
RESULTS: The percentage of l-selectin-expressing CD4+ T cells was significantly lower in patients treated long-term with natalizumab (40.2%) when compared with patients not receiving natalizumab treatment (47.2%; p = 0.016) or healthy controls (61.0%; p < 0.0001). ...
RESULTS: The percentage of l-selectin-expressing CD4+ T cells was significantly lower in patients treated long-term with natalizumab …
Immune therapy of multiple sclerosis--future strategies.
Meuth SG, Göbel K, Wiendl H. Meuth SG, et al. Among authors: gobel k. Curr Pharm Des. 2012;18(29):4489-97. doi: 10.2174/138161212802502198. Curr Pharm Des. 2012. PMID: 22612746 Review.
These substances reduce relapse rates, side-effects are tolerated by most patients and - after more than 15 years of experience - the long-term safety profile for these drugs can be appraised as very good. ...
These substances reduce relapse rates, side-effects are tolerated by most patients and - after more than 15 years of experience - the long- …